ITM Isotope Technologies Munich and NTP Radioisotopes in South Africa have renewed a long-standing technology transfer and license agreement for the production of the medical radioisotope non-carrier-added lutetium-177 (Lu-177).
Under the agreement, ITM grants NTP the use of intellectual property rights related to the manufacturing of the Lu-177 within the Republic of South Africa and other selected territories, the company said.
In addition, ITM said the two firms have entered a new manufacturing and supply partnership that involves irradiating ytterbium-176 and the SAFARI-1 nuclear reactor operated by Necsa, NTP Radioisotopes' parent company.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
